Research
Hormonal
GLP-1 receptor agonists reduce food intake, increase satiety, delay gastric emptying, and improve glucose tolerance, leading to weight loss in humans.
GLP-1 receptor agonists are a proven, FDA-approved treatment for obesity and type 2 diabetes. They work by reducing appetite and improving metabolic function. Consult a healthcare provider to see if this treatment is appropriate for you.
GoodSupportsHIGH confidence
In humans, exogenous GLP-1 reduces food intake, increases satiety, delays gastric emptying, and improves glucose tolerance, with weight loss effects demonstrated in 25 meta-analyses... Recently, GLP-1 receptor agonists have been approved for treatment of type 2 diabetes and obesity.
Why this rating
Supported by 25 meta-analyses and clinical approvals, indicating strong evidence.
Source
Significance of neuroendocrine systems and the gut-brain axis (GBA) in the regulation of obesity
Hanwei Zhao et al. · PeerJ · 2026
DOI 10.7717/peerj.20400
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Brown adipose tissue (BAT) activation and white-to-brown adipose tissue transformation reduce obesity risk by increasing energy expenditure and improving glucose homeostasis.Moderate
- Leptin resistance, caused by impaired blood-brain barrier transport or receptor signaling defects, prevents the hormone from suppressing appetite and regulating body weight in obese individuals.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →